文献速递中医内科中药与中成药合理使用

中药注射剂联合曲美他嗪治疗病毒性心肌炎的疗效与安全性:网状Meta分析

Evaluation of the Efficacy and Safety of Chinese Herbal Injection Combined With Trimetazidine for Viral Myocarditis: A Network Meta-Analysis.
PubMed 文献 · Front Pharmacol · 2021-04-29

该网状Meta分析纳入29项随机对照试验共2687例病毒性心肌炎患者,评估中药注射剂联合曲美他嗪的疗效与安全性。结果显示联合治疗可能提高有效率并更好降低心肌损伤标志物,安全性无显著差异,但部分研究缺乏安全监测。

要点

  • 中药注射剂联合曲美他嗪可能提高病毒性心肌炎治疗有效率。
  • 联合治疗对降低肌酸激酶、CK-MB和乳酸脱氢酶可能更优。
  • 安全性无显著差异,但部分研究安全监测不足。

核心结论

  • 中药注射剂联合曲美他嗪在病毒性心肌炎治疗中可能有治疗价值。
  • 参麦注射液、黄芪注射液、丹参川芎嗪注射液可能是最有效的中药注射剂。

研究设计与样本

  • 网状Meta分析,检索PubMed、Cochrane Library、Embase、CNKI、万方、VIP、CBM数据库至2020年9月1日。
  • 纳入29项随机对照试验,共2687例患者。

主要发现

  • 与常规治疗或常规治疗联合曲美他嗪相比,中药注射剂联合曲美他嗪似乎疗效更好,有效率更高,且对肌酸激酶、CK-MB和乳酸脱氢酶降低更优。
  • 基于累积排序概率曲线下面积,参麦注射液联合曲美他嗪在有效率方面似乎最优。
  • 黄芪注射液或丹参川芎嗪注射液联合曲美他嗪在降低心肌损伤标志物方面似乎最有效。
  • 干预措施间安全性无显著差异。

临床怎么用

  • 可考虑在病毒性心肌炎治疗中联合使用中药注射剂与曲美他嗪以可能提高疗效。
  • 参麦注射液、黄芪注射液、丹参川芎嗪注射液可能作为优先选择的中药注射剂。

局限性

  • 部分纳入研究缺乏安全监测,无法充分评估某些干预措施的安全性。
  • 需要进一步临床研究证实这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Viral myocarditis (VMC) is a common emergency of cardiovascular disease. Current treatment for VMC includes the prohibition of exercise plus supportive and symptomatic treatment, given the lack of specific antiviral therapeutic options and insufficient evidence for the use of novel immunosuppressive therapies. Trimetazidine, a drug used to improve myocardial energy metabolism, is frequently used for the treatment of viral myocarditis. In China, Chinese herbal injections (CHIs) are often used in combination with trimetazidine. Therefore, we evaluate the efficacy and safety of CHI combined with trimetazidine in the treatment of VMC through the method of network meta-analysis. Methods: We searched PubMed, the Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Scientific Journals Full-text Database (VIP), and China Biology Medicine Database (CBM) databases from inception to September 1, 2020, to identify eligible randomized controlled trials. The Cochrane risk of bias tool was used to assess the risk of bias among selected studies and the Stata 16.0 software was used to perform the network meta-analysis. Results: A total of 29 studies were included, representing data from 2,687 patients. The effectiveness rate, level of myocardial injury marker, and the adverse reaction rate were evaluated. Compared with conventional treatment or conventional treatment combined with trimetazidine, CHIs combined with trimetazidine appeared to have a better therapeutic effect, with higher effectiveness rate and better reduction of the levels of creatine kinase, creatine kinase-MB, and lactate dehydrogenase. Based on surface under the cumulative ranking, Shenmai injection combined with trimetazidine appeared to be superior in terms of effective rate, while Astragalus injection or Salviae miltiorrhizae and ligustrazine hydrochloride injection combined with trimetazidine appeared most effective in reducing myocardial injury markers. There was no significant difference in safety between the interventions. However, a lack of safety monitoring in some selected studies meant that the safety of some interventions could not be fully evaluated. Conclusion: CHIs combined with trimetazidine may have therapeutic value in the treatment of viral myocarditis, and Shenmai injection, Astragalus injection, and Salviae miltiorrhizae and ligustrazine hydrochloride injection may represent the most effective CHIs. Further clinical investigation is required to confirm these results.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wu K, Deng D, Yu B, et al. Evaluation of the Efficacy and Safety of Chinese Herbal Injection Combined With Trimetazidine for Viral Myocarditis: A Network Meta-Analysis. Front Pharmacol. 2021. PMID: 33995029. doi:10.3389/fphar.2021.630896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。